Breaks Categories: News

TuesdayAug 12, 2025 9:45 am

NetworkNewsBreaks – ECGI Holdings Inc. (OTC: ECGI) Portfolio Company Payday Fantasy to Launch NFL, NCAAF Play and Marketplace

ECGI Holdings (OTC: ECGI), a diversified holding company focused on high-upside opportunities in transformative markets, announced that its portfolio company, Payday Fantasy, will soon add NFL and NCAA Football (NCAAF) data to enable play on those leagues, alongside the debut of its fantasy sports marketplace. The launches are timed with the start of the NFL regular season, when fantasy sports activity peaks, creating momentum to drive adoption and brand recognition. Following rollout, Payday Fantasy will execute a marketing campaign aimed at accelerating user growth during football’s busiest stretch. The global fantasy sports market, valued at $24.8 billion in 2024, is…

Continue Reading

TuesdayAug 12, 2025 9:35 am

NetworkNewsBreaks – InvestorNewsBreaks – Branded Legacy, Inc. (OTC: BLEG) Completes Acquisition of Bio Legacy Evaluative Group, Expanding into Biotech and Medical Devices

Branded Legacy (OTC: BLEG), a diversified holdings company in the health and wellness sector, has completed its acquisition of Bio Legacy Evaluative Group, formerly Menlo Health, in an all-stock deal valued at $1.5 million in Preferred D shares. The transaction, closed July 31, 2025, positions Branded Legacy to address global health challenges such as the addiction epidemic and vaccine distribution inefficiencies. Under CEO Amin Janmohamed, Bio Legacy brings a patented all-in-one intranasal naloxone device targeting a market projected to grow from $371 million in 2022 to over $1.16 billion by 2032, along with technology for nasal delivery of vaccines and cold-chain…

Continue Reading

TuesdayAug 12, 2025 9:15 am

NetworkNewsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) to Host Webcast and Investor Q&A After Q2 2025 Results

Newton Golf Company (NASDAQ: NWTG), a technology-forward golf company focused on performance-driven innovation, will host a webcast and investor Q&A session following the release of its second quarter 2025 financial results. To view the full press release, visit https://nnw.fm/h9N7G About Newton Golf At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf clubs that deliver unmatched stability, control, and performance.…

Continue Reading

MondayAug 11, 2025 12:33 pm

NetworkNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Hits $100 Million in Transaction Volume for Licensed Coin-In/Coin-Out Services 

Solowin (NASDAQ: SWIN), a financial services firm bridging traditional and digital assets, announced that its wholly owned subsidiary Solomon JFZ (Asia) Holdings Limited (“Solomon”) has processed $100 million in total transaction volume since launching licensed coin-in and coin-out services in Hong Kong. The milestone follows Solomon’s recent licensing from the Hong Kong Securities and Futures Commission, enabling regulated fiat-to-digital asset connectivity under the city’s stringent compliance standards. Solomon’s platform meets rigorous asset custody, AML/KYC, and market integrity requirements while holding the majority of client assets in cold storage. Positioned to leverage its first-mover advantage, Solowin plans to deepen partnerships with…

Continue Reading

MondayAug 11, 2025 11:34 am

NetworkNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Drivers Deliver Strong Results at Grand Prix of Portland 

SEGG Media (NASDAQ: SEGG, LTRYW) saw its Lottery.com and Sports.com brands prominently displayed across the NTT INDYCAR and INDY NXT by Firestone paddocks this weekend as SEGG-backed drivers posted solid performances in the final road course race of the 2025 season at the BitNile.com Grand Prix of Portland. Callum Ilott (PREMA Racing) climbed 18 positions from P24 to finish P6, matching his career-best result and securing PREMA’s fourth straight top-10. Louis Foster (Rahal Letterman Lanigan Racing) recovered from an early spin to finish P13, maintaining his lead in the INDYCAR Rookie of the Year standings. In his Portland debut, Seb…

Continue Reading

MondayAug 11, 2025 10:58 am

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NRX-100 for treating suicidal ideation in patients with depression, including bipolar depression—a 10-fold expansion from its prior 2017 designation for use with NRX-101 in suicidal bipolar depression. The FDA’s determination, based on preliminary data, also supports potential eligibility for the Commissioner’s National Priority Voucher Program and the Accelerated Approval Program. Controlled trials licensed by NRx showed NRX-100 (IV ketamine) reduced suicidal ideation significantly, with one Columbia University study reporting a 55% response rate versus 30% for active comparator…

Continue Reading

MondayAug 11, 2025 10:36 am

NetworkNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS, WLDSW) Secures U.S. Patent for Gesture and Voice-Controlled Neural Interface 

Wearable Devices (NASDAQ: WLDS, WLDSW), a technology growth company specializing in AI-powered touchless sensing wearables, announced that the United States Patent and Trademark Office has granted its patent titled “Gesture and Voice-Controlled Interface Device.” The patent covers proprietary neural interface technology enabling gesture-based control and real-world physical measurements from the wrist, including object weight estimation, torque and force measurement, and integration with voice commands, XR embodiment, and brain-computer interface innovations. The protected technology supports applications in XR immersion, industrial efficiency, logistics accuracy, and assistive solutions for individuals with severe disabilities. The grant advances the company’s IP strategy and reinforces its…

Continue Reading

MondayAug 11, 2025 9:50 am

NetworkNewsBreaks – Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix Inc. (NASDAQ: SNGX) Advances Proprietary Clinical Programs

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted last week in a report from Alliance Global Partners (“AGP”), which maintained its Buy rating for Soligenix and raised SNGX’s price target to $10 per share. According to the report, the increase was based on the increasing valuation of HyBryte(TM) for the treatment of early-stage cutaneous T cell lymphoma (“CTCL”) and new estimated valuation for Soligenix’s SGX945, a treatment for Behçet's disease. According to the report, SNGX’s phase 3 FLASH2 trial is on track to have topline results announced next year. AGP noted that in December 2024, Soligenix…

Continue Reading

MondayAug 11, 2025 9:20 am

NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Steps Aside Temporarily to Run for Irish Presidency

Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will step aside for three months to pursue candidacy in the Irish Presidential election, with nomination hearings and voting taking place in September and October. Co-Founder and Chairman Serguei Melnik, a corporate strategy expert with over 20 years in capital markets, will assume CEO duties during this period, guiding the company toward its 2026 NDA filing target. Sheridan emphasized confidence in the leadership team, noting continued progress on AVERSA Fentanyl, which the FDA recently granted a meeting request for. AVERSA Fentanyl is positioned to be the first abuse-deterrent opioid patch, designed to…

Continue Reading

MondayAug 11, 2025 9:10 am

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Q2 2025 Results and Business Highlights

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines to metastatic disease sites, reported a Q2 2025 net loss of $5.7 million, or $1.99 per share, compared to a net loss of $7.4 million, or $16.75 per share, in Q2 2024. R&D expenses were $2.6 million versus $2.2 million last year, while G&A expenses were $3.1 million compared to $3.6 million. Calidi ended the quarter with $5.3 million in cash and $0.1 million in restricted cash. Recent highlights include new preclinical data on CLD-401 from the proprietary RedTail platform, showing enhanced efficacy through…

Continue Reading